BioNexus Gene Lab Corp. (BGLC) Stock Price & Analysis
BioNexus Gene Lab Corp. (BGLC) closed at USD 1.19 on Friday, October 23, 2026, up 0.00% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.19; the Oct 23, 2026 session ranged USD 1.19–1.19 on volume of 2,231 shares. Market capitalization is $3.49M, with a 52-week range of USD 1.07–5.67 (NCM). Source: Nexqual, retrieved October 24, 2026 at 16:36 UTC.
Also available as compact Markdown for AI agents: nexqual.com/BGLC.md
Key facts (BGLC)
- Last four reported quarters (through Jun 30, 2026): revenue $3.1M, net income -$2.6M (-82.4% margin), free cash flow -$854K (SEC filings).
- Analysts: None.
- Total return with dividends: 1Y -76.6% vs S&P 500 +13.4%; 5Y -99.5% vs S&P 500 +76.9%.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (BGLC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M | $3.1M |
| Gross profit | $2.3M | $1.3M | $1.3M | $1.3M | $1.1M | — |
| Operating income | $1.1M | -$291K | -$2.6M | -$1.6M | -$3.0M | -$2.6M |
| Net income | $752K | -$356K | -$2.6M | -$1.6M | -$3.0M | -$2.6M |
| EPS (diluted) | — | — | -$0.17 | -$0.09 | — | — |
| Free cash flow | $6K | $552K | -$2.0M | -$2.3M | -$1.9M | -$854K |
| Gross margin | 17.0% | 11.5% | 13.6% | 13.6% | 14.6% | — |
| Operating margin | 7.9% | -2.7% | -26.5% | -16.5% | -39.9% | -81.8% |
| Net margin | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% | -82.4% |
| Revenue growth | +17.3% | -18.2% | -10.6% | -2.7% | -21.9% | — |
| Cash + short-term investments | $2.1M | $2.1M | $4.5M | $2.9M | $2.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (BGLC)
P/S 1.1x · P/B 0.5x · FCF yield -24.45% · Earnings yield -73.77%
Analysts (BGLC)
Consensus None.
Total return (dividends reinvested) (BGLC)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | -76.6% | -99.5% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | -76.7% | -65.0% |
| Volatility (annualized) | 68.7% | 161.6% |
| Max drawdown | -78.3% (Nov 2025→Oct 2026) | -99.5% (Dec 2021→Oct 2026) |
BGLC revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Myanmar (Burma) | $63,717 | 83.7% | -96.5% |
| South Africa | $12,439 | 16.3% | — |
| Total revenue | $76,156 | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
BGLC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 24, 2026 at 16:36 UTC)
| Price | USD 1.19 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 1.19 |
| Open | USD 1.19 |
| Day Range | USD 1.19 – 1.19 |
| 52-Week Range | USD 1.07 – 5.67 |
| Volume | 2,231 shares |
| Market Cap | $3.49M |
| Exchange | NCM |
Technical Analysis (BGLC)
Nexqual's technical model rates BGLC "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 24, 2026 at 16:36 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 42.02 (neutral) |
| vs SMA50 | Below (USD 1.4) |
| MACD | -0.06 (negative) |
Analyst Ratings (BGLC)
Wall Street analysts rate BGLC "None", per Nexqual as of October 24, 2026 at 16:36 UTC.
| Consensus Rating | None |
|---|
Earnings (BGLC)
Source: Nexqual, October 24, 2026 at 16:36 UTC.
Financials & Fundamentals (BGLC)
| Total Revenue | $3.13M |
|---|---|
| Revenue Growth (latest quarter, YoY) | -96.60% |
| Gross Margin | +12.34% |
| Operating Margin | -398.69% |
| Profit Margin | -82.36% |
| ROE | -33.66% |
| Debt / Equity | 0.04 |
| Current Ratio | 6.08 |
| Total Cash | $3.52M |
| Total Debt | $323,197 |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$853,600 (-27.3% of revenue) |
Source: Nexqual, October 24, 2026 at 16:36 UTC.
Financial Health Score (BGLC)
Nexqual rates BioNexus Gene Lab Corp.'s overall financial health "Weak" across five dimensions, as of October 24, 2026 at 16:36 UTC.
| Growth | Critical — Revenue -97% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash, no debt |
| Cash Flow | Weak — FCF negative: -$854K (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -34%, ROA -19.0% |
Ownership (BGLC)
| Insider Ownership | +44.72% |
|---|---|
| Institutional Ownership | +0.49% |
| Shares Outstanding | 2.93M |
| Float | 1.67M |
| Short % of Float | +0.40% |
Source: Nexqual, October 24, 2026 at 16:36 UTC.
Leadership (BGLC)
BioNexus Gene Lab Corp. is led by Su-Leng Tan, CEO, President, Secretary & Director, per Nexqual as of October 24, 2026 at 16:36 UTC.
| CEO, President, Secretary & Director | Su-Leng Tan |
|---|---|
| Chief Financial Officer | Set Fui Chong |
| Managing Director | Too Kam Tham |
Major Backers & Investors (BGLC)
Notable institutional backers of BioNexus Gene Lab Corp. include HRT Financial LP, according to Nexqual as of October 24, 2026 at 16:36 UTC.
Active Investors
| Investor | Stake |
|---|---|
| HRT Financial LP | 0.49% |
Source: Nexqual, October 24, 2026 at 16:36 UTC.
From BioNexus Gene Lab Corp.'s Latest SEC 10-K Filing (filed 2026-04-14)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary algorithm software then analyzes this collected data and processes checked by the laboratory manager to ensure all the steps are followed in the deriving predictive model for each disease condition.
- While we have attempted to protect the unpatented proprietary technology that we develop or acquire and will continue to attempt to protect future proprietary technology through patents, copyrights, and trade secrets, we believe that our success will depend, to a large extent, upon continued innovation and technological expertise.
- We take advantage of profiling these changes, which enables us to identify unique molecular signatures (biomarkers) reflecting disease activity which can then be used to develop disease-specific molecular diagnostic assays.
Partnerships
- The Company concurrently entered into an Equity Distribution Agreement with Maxim Group LLC ("Agent"), pursuant to which the Company may offer and sell, from time to time, shares of its common stock, no par value (the "Common Stock"), having an aggregate offering price of up to $20,000,000 through the Agent, acting as the Company's exclusive sales agent (the "ATM Program").
- In November 2025, the Company entered into a Share Subscription and Shareholders' Agreement with Fidelion Diagnostics Pte.
Legal & Regulatory Risks (Item 1A, quoted)
- We may be adversely impacted by changes in laws and regulations, or in their application.
- The marketing, sale and use of MRNA Scientific's products and services could result in substantial damages arising from products or service liability or professional liability claims, that exceed MRNA Scientific's resources.
- We may be exposed to product returns and product liability claims and latent defect liability claims.
- We may be subject to intellectual property claims, which are extremely costly to defend, could require us to pay significant damages and could limit the company's ability to use certain technologies in the future.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BCPC | Balchem Corporation | USD 177 | ▲ 2.18% |
| SXT | Sensient Technologies Corporati | USD 132.65 | ▲ 1.31% |
| AXTA | Axalta Coating Systems Ltd. | USD 34.14 | ▼ 2.6% |
| EMN | Eastman Chemical Company | USD 64.93 | ▼ 0.58% |
| NEU | NewMarket Corp | USD 870.6 | ▼ 0.65% |
| ESI | Element Solutions Inc. | USD 33.21 | ▲ 0.3% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 16:36 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt